Data / Drug companies / Shionogi Pharma Co., Ltd.
Shionogi Pharma Co., Ltd.: 10 products in the FDA NDC directory, labeler code 53044
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Shionogi Pharma Co., Ltd. (labeler code 53044) lists 10 products in the FDA National Drug Code Directory. By type: 6 bulk ingredients, 4 drugs for further processing. Its main marketing category is bulk ingredients. The newest product started marketing on October 30, 2026.
The request: Watch Shionogi Pharma Co., Ltd. (FDA labeler code 53044): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 53044
- Products in commercial distribution
- 10
- Packages
- 10
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- June 9, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 6 | 60% |
| Drugs for further processing | 4 | 40% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 6 | 60% |
| Drugs for further processing | 4 | 40% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 6 | 60% |
| Tablet, coated | 3 | 30% |
| Granule, for suspension | 1 | 10% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ensitrelvir fumaric acid | 53044-006 | Powder | Bulk ingredients | October 30, 2026 |
| Baloxavir marboxil | 53044-877 | Tablet, coated | Drugs for further processing | September 1, 2021 |
| Baloxavir marboxil | 53044-836 | Granule, for suspension | Drugs for further processing | July 23, 2020 |
| Cefiderocol sulfate tosylate | 53044-005 | Powder | Bulk ingredients | January 31, 2020 |
| Baloxavir marboxil | 53044-004 | Powder | Bulk ingredients | December 24, 2018 |
| Baloxavir marboxil | 53044-860 | Tablet, coated | Drugs for further processing | October 24, 2018 |
| Baloxavir marboxil | 53044-828 | Tablet, coated | Drugs for further processing | October 24, 2018 |
| Lusutrombopag | 53044-003 | Powder | Bulk ingredients | August 26, 2018 |
| Naldemedine tosylate | 53044-002 | Powder | Bulk ingredients | March 23, 2017 |
| Dolutegravir sodium | 53044-001 | Powder | Bulk ingredients | June 9, 2016 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.